About this episode
If your midlife metabolism suddenly stopped playing by the old rules, you’re not imagining it. In this episode, Dr. Brighten breaks down how perimenopause and menopause shift insulin sensitivity, fat distribution, appetite, and recovery and where glucagon-like peptide-1 (GLP-1) receptor agonists (think semaglutide/Ozempic, Wegovy, liraglutide, tirzepatide as a related incretin therapy) can fit safely alongside hormone therapy, lifting, protein, and smart lab work. You’ll leave with a practical checklist you can take to your clinician, plus a clear understanding of how to protect muscle, heart, and brain while losing fat. Now, to be clear, this episode isn’t about convincing anyone to use a GLP-1. It is about making sure you know how they work, what the risks are, and what you MUST do to stay healthy on them. You’ll hear the new science of what role they play in cardiovascular disease prevention. 🎧For the entire show notes + links mentioned in the episode, please visit: https://drbrighten.com/podcasts/glp-1-weight-loss-in-menopause/ 👩🏻⚕️ Follow Dr. Jolene Brighten: 💻 Website: https://www.drbrighten.com 📸 Instagram: https://www.instagram.com/drjolenebrighten 🎥 TikTok: https://www.tiktok.com/@drjolenebrighten 🧵Threads: https://www.threads.net/@drjolenebrighten 🌟 Grab my free hormone friendly recipes here! https://drbrighten.com/hormonekit/ 👉 If you found this episode valuable, drop a comment below to tell us what you loved most, and share it with a friend! Let’s spread the knowledge. 💬✨ Learn more about your ad choices. Visit megaphone.fm/adchoices